Oral chemotherapy with idarubicin plus cyclophosphamide in advanced breast cancer

P. Pronzato, G. Bertelli, D. Amoroso, C. Pennucci, G. Gardin, T. Guido, P. Rosso

Research output: Contribution to journalArticlepeer-review


An oral chemotherapy schedule based on idarubicin and cyclophosphamide was evalutated in 31 advanced breast cancer patients. Out of 27 patients evaluable for response, 1 (3.7%) achieved a complete response and 5 (18.5%) a partial response, with an objective response rate of 22.2% (95% confidence limits 8.6-42.3%). The median time to progression was 7 months (range 3-12). Fourteen patients (51.9%) showed a disease stabilization, and 7 progressed (25.9%). Toxicity was mild. Considering the low response rate, but also the advantages of oral chemotherapy and the mild toxicity observed, oral idarubicin plus cyclophosphamide can be considered as a second-choice regimen in advanced breast cancer.

Original languageEnglish
Pages (from-to)449-453
Number of pages5
Issue number6
Publication statusPublished - 1991


  • Breast cancer
  • Cyclophosphamide
  • Idarubicin
  • Oral chemotherapy

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Oral chemotherapy with idarubicin plus cyclophosphamide in advanced breast cancer'. Together they form a unique fingerprint.

Cite this